Banco Santander (SAN) 7.02 $SAN
Santander And New England Revolution Launch 2015 Santander Soccer Scholars Program
PR Newswire - Wed Apr 22, 12:09PM CDT
In celebration of its commitment to education and the successful start to the New England Revolution's 2015 season, Santander Bank, N.A. today announced the launch of its second consecutive Santander Soccer ScholarsSM program. The program gives New England youth the chance to win a unique VIP Match Day experience with the Revolution in recognition of their academic achievement.
SAN: 7.02 (-0.02)
Santander Holdings USA announces preferred stock dividend of USD0.45625 per depositary share
M2 - Wed Apr 22, 3:53AM CDT
A wholly-owned subsidiary of diversified retail and commercial bank, Banco Santander SA (NYSE:SAN), Santander Holdings USA Inc's board of directors authorised a dividend of USD0.45625 per depositary share on the company's series C non-cumulative perpetual preferred stock (NYSE:SOVPRC), it revealed on Tuesday.
SAN: 7.02 (-0.02)
Santander Holdings USA Declares Quarterly Dividend On Preferred Stock
PR Newswire - Tue Apr 21, 9:47AM CDT
Santander Holdings USA, Inc. (SHUSA), parent company of Santander Bank, N.A., announced today that its Board of Directors declared a dividend on SHUSA's Preferred Stock. A dividend payment of $0.45625 per depositary share is payable on May 15, 2015 to holders of record on May 1, 2015 for SHUSA's Series C Non-Cumulative Perpetual Preferred Stock (NYSE: SOVPRC).
SC: 22.68 (+0.05), SAN: 7.02 (-0.02)
Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease
Business Wire - Tue Apr 21, 8:00AM CDT
Genzyme, a Sanofi company, announced today that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being investigated for the treatment of Fabry disease. The safety, tolerability and pharmacokinetics of GZ/SAR402671 will also be assessed. Genzyme plans to enroll nine treatment-naive male adult patients with Fabry disease in this international, multicenter study.
SAN: 7.02 (-0.02), SNY: 51.59 (+0.03)
GE Q1 Earnings Beat on Sustained Industrial Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 9:37AM CDT
A massive restructuring in its operating portfolio with a re-focus on core operations enabled General Electric Company (GE) to report relatively modest first-quarter 2015 results.
SAN: 7.02 (-0.02), CODI: 17.12 (-0.04), GE: 26.91 (+0.29), CSL: 94.86 (+0.78)
Top Dividend Global Dogs Give 69.07% Edge To 5 In April
Fredrik Arnold - at Seeking Alpha - Wed Apr 15, 8:23PM CDT
SID: 2.13 (+0.16), SAN: 7.02 (-0.02), E: 36.62 (+0.43), FLY: 14.87 (-0.01), EC: 16.14 (+0.08), HSBC: 45.61 (+0.01), ELP: 11.60 (+0.20)
10 Top Dividend Global Dogs Show 11% To 208% April Upsides
Fredrik Arnold - at Seeking Alpha - Wed Apr 15, 7:02PM CDT
E: 36.62 (+0.43), BAK: 8.04 (+0.21), EC: 16.14 (+0.08), FLY: 14.87 (-0.01), ELP: 11.60 (+0.20), HSBC: 45.61 (+0.01), SID: 2.13 (+0.16), TGA: 4.33 (-0.04), SAN: 7.02 (-0.02), CIG: 4.88 (+0.14), CPL: 13.80 (+0.44), TOT: 52.01 (-0.23), BHP: 47.80 (+1.55), BCE: 44.51 (+0.30), RIO: 43.39 (+1.68)
Genzyme to Present New Long-Term Data on Aubagio(R) (teriflunomide) and Lemtrada(R) (alemtuzumab) at AAN
Business Wire - Mon Apr 13, 8:00AM CDT
Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio(R) (teriflunomide) and Lemtrada(R) (alemtuzumab), will be featured during the 67th annual meeting of the American Academy of Neurology (AAN) being held in Washington, D.C. April 18-25. The company will present 30 platform and poster presentations from its MS franchise, including 19 on Lemtrada, 10 on Aubagio and one pipeline presentation. Key data being presented at AAN include:
SAN: 7.02 (-0.02), SNY: 51.59 (+0.03)
Banco Santander Announces Its Commitment To Launch A Social Economy Initiative With Georgetown University
PR Newswire - Tue Apr 07, 4:45PM CDT
Banco Santander, through Santander Universities, signed today a Memorandum of Understanding with Georgetown University, to support a new initiative on the social economy. The initiative will focus on issues of social banking, social finance, and social entrepreneurship. This Memorandum was signed by Ana Botin, Executive Chairman of Banco Santander and John DeGioia, President of Georgetown University.
SAN: 7.02 (-0.02)
RI Governor, Providence Mayor And Local Business Leaders Discuss Rhode Island Economy At Santander And Greater Providence Chamber Of Commerce Event
PR Newswire - Tue Apr 07, 1:14PM CDT
Santander Bank, N.A. and the Greater Providence Chamber of Commerce today hosted their 15th annual meeting for the business community focused on the region's economic outlook. Over 350 attendees were surveyed in real time regarding their expectations for the local economy in 2015, as well as plans for their respective businesses over the coming year.
SAN: 7.02 (-0.02)
Why Santander Is A Strong Buy From Here
Chris Lau - at Seeking Alpha - Tue Apr 07, 2:58AM CDT
SAN: 7.02 (-0.02)
Over 300 Local Business Leaders Discuss Massachusetts Economy at Santander and Greater Boston Chamber of Commerce Event
PR Newswire - Thu Apr 02, 2:03PM CDT
Santander Bank, N.A., and the Greater Boston Chamber of Commerce today hosted their 15th annual meeting for the business community focused on the region's economic outlook. Over 300 attendees were surveyed in real time regarding their expectations for the local economy in 2015 as well as plans for their respective businesses over the coming year.
SAN: 7.02 (-0.02)
Can Lender Santander Consumer USA Rev Up Car Loans?
at Investor's Business Daily - Tue Mar 31, 4:47PM CDT
When it comes to making auto loans to nonprime borrowers, Santander Consumer USA Holdings has been moving in the fast lane without hitting many speed bumps. Santander Consumer USA (SC), which went public in January 2014, is a consumer finance company...
SAN: 7.02 (-0.02), SC: 22.68 (+0.05), CACC: 211.50 (+5.39), FCAU: 16.29 (+0.02), IX: 82.78 (+3.06)
Why I Am Sticking With Santander
Nelson Alves - at Seeking Alpha - Tue Mar 31, 1:30AM CDT
SAN: 7.02 (-0.02)
Banco Santander Down 20.4% Since SmarTrend Downtrend Call (SAN)
Comtex SmarTrend(R) - Mon Mar 30, 9:35AM CDT
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 6 months, Banco Santander has returned 20.38% as of today's recent price of $7.54.
SAN: 7.02 (-0.02)
BoE unveils U.K. bank stress tests
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:17AM CDT
BCS: 15.35 (+0.06), SAN: 7.02 (-0.02), HSBC: 45.61 (+0.01), RBS: 10.53 (-0.06), LYG: 4.75 (-0.03)
Pre-Market Scans on Banks Stocks -- Banco Santander, Lloyds Banking, HSBC Holdings, Synovus Financial, and Citizens Financial
PR Newswire - Mon Mar 30, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SAN: 7.02 (-0.02), CFG: 25.49 (+0.45), SNV: 28.21 (+0.06), HSBC: 45.61 (+0.01), LYG: 4.75 (-0.03)
'Fast Money' Recap: The 3 Reasons Stocks Tanked Wednesday
at The Street - Thu Mar 26, 4:00AM CDT
The trading panel discussed the declines in biotech, transports and semiconductors.
FDX: 170.01 (+0.10), BIIB: 423.57 (+1.46), MU: 29.50 (+0.95), OIH: 36.92 (+0.42), XBI: 232.63 (-0.32), AMGN: 169.10 (+0.64), BNO: 22.89 (+0.29), IBB: 363.84 (-0.66), SMH: 57.23 (+1.02), INTC: 32.70 (+0.27), TLT: 127.72 (-1.98), CELG: 115.54 (+0.72), NVDA: 22.31 (+0.25), SAN: 7.02 (-0.02), SAVE: 77.25 (+0.19), GILD: 104.18 (-1.02), QCOM: 68.94 (+0.37), IYT: 158.66 (+0.89)
Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age
PR Newswire - Wed Mar 25, 11:15AM CDT
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved use of Quadracel(TM) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.
SAN: 7.02 (-0.02), SNY: 51.59 (+0.03)
Santander: Global Retail Bank With Leading Cost Efficiency
Junius - at Seeking Alpha - Wed Mar 25, 6:52AM CDT
SAN: 7.02 (-0.02)
Santander And New England Revolution Launch 2015 Santander Soccer Scholars Program
PR Newswire - Wed Apr 22, 12:09PM CDT
In celebration of its commitment to education and the successful start to the New England Revolution's 2015 season, Santander Bank, N.A. today announced the launch of its second consecutive Santander Soccer ScholarsSM program. The program gives New England youth the chance to win a unique VIP Match Day experience with the Revolution in recognition of their academic achievement.
SAN: 7.02 (-0.02)
Santander Holdings USA announces preferred stock dividend of USD0.45625 per depositary share
M2 - Wed Apr 22, 3:53AM CDT
A wholly-owned subsidiary of diversified retail and commercial bank, Banco Santander SA (NYSE:SAN), Santander Holdings USA Inc's board of directors authorised a dividend of USD0.45625 per depositary share on the company's series C non-cumulative perpetual preferred stock (NYSE:SOVPRC), it revealed on Tuesday.
SAN: 7.02 (-0.02)
Santander Holdings USA Declares Quarterly Dividend On Preferred Stock
PR Newswire - Tue Apr 21, 9:47AM CDT
Santander Holdings USA, Inc. (SHUSA), parent company of Santander Bank, N.A., announced today that its Board of Directors declared a dividend on SHUSA's Preferred Stock. A dividend payment of $0.45625 per depositary share is payable on May 15, 2015 to holders of record on May 1, 2015 for SHUSA's Series C Non-Cumulative Perpetual Preferred Stock (NYSE: SOVPRC).
SC: 22.68 (+0.05), SAN: 7.02 (-0.02)
Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease
Business Wire - Tue Apr 21, 8:00AM CDT
Genzyme, a Sanofi company, announced today that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being investigated for the treatment of Fabry disease. The safety, tolerability and pharmacokinetics of GZ/SAR402671 will also be assessed. Genzyme plans to enroll nine treatment-naive male adult patients with Fabry disease in this international, multicenter study.
SAN: 7.02 (-0.02), SNY: 51.59 (+0.03)
GE Q1 Earnings Beat on Sustained Industrial Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 9:37AM CDT
A massive restructuring in its operating portfolio with a re-focus on core operations enabled General Electric Company (GE) to report relatively modest first-quarter 2015 results.
SAN: 7.02 (-0.02), CODI: 17.12 (-0.04), GE: 26.91 (+0.29), CSL: 94.86 (+0.78)
Top Dividend Global Dogs Give 69.07% Edge To 5 In April
Fredrik Arnold - at Seeking Alpha - Wed Apr 15, 8:23PM CDT
SID: 2.13 (+0.16), SAN: 7.02 (-0.02), E: 36.62 (+0.43), FLY: 14.87 (-0.01), EC: 16.14 (+0.08), HSBC: 45.61 (+0.01), ELP: 11.60 (+0.20)
10 Top Dividend Global Dogs Show 11% To 208% April Upsides
Fredrik Arnold - at Seeking Alpha - Wed Apr 15, 7:02PM CDT
E: 36.62 (+0.43), BAK: 8.04 (+0.21), EC: 16.14 (+0.08), FLY: 14.87 (-0.01), ELP: 11.60 (+0.20), HSBC: 45.61 (+0.01), SID: 2.13 (+0.16), TGA: 4.33 (-0.04), SAN: 7.02 (-0.02), CIG: 4.88 (+0.14), CPL: 13.80 (+0.44), TOT: 52.01 (-0.23), BHP: 47.80 (+1.55), BCE: 44.51 (+0.30), RIO: 43.39 (+1.68)
Genzyme to Present New Long-Term Data on Aubagio(R) (teriflunomide) and Lemtrada(R) (alemtuzumab) at AAN
Business Wire - Mon Apr 13, 8:00AM CDT
Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio(R) (teriflunomide) and Lemtrada(R) (alemtuzumab), will be featured during the 67th annual meeting of the American Academy of Neurology (AAN) being held in Washington, D.C. April 18-25. The company will present 30 platform and poster presentations from its MS franchise, including 19 on Lemtrada, 10 on Aubagio and one pipeline presentation. Key data being presented at AAN include:
SAN: 7.02 (-0.02), SNY: 51.59 (+0.03)
Banco Santander Announces Its Commitment To Launch A Social Economy Initiative With Georgetown University
PR Newswire - Tue Apr 07, 4:45PM CDT
Banco Santander, through Santander Universities, signed today a Memorandum of Understanding with Georgetown University, to support a new initiative on the social economy. The initiative will focus on issues of social banking, social finance, and social entrepreneurship. This Memorandum was signed by Ana Botin, Executive Chairman of Banco Santander and John DeGioia, President of Georgetown University.
SAN: 7.02 (-0.02)
RI Governor, Providence Mayor And Local Business Leaders Discuss Rhode Island Economy At Santander And Greater Providence Chamber Of Commerce Event
PR Newswire - Tue Apr 07, 1:14PM CDT
Santander Bank, N.A. and the Greater Providence Chamber of Commerce today hosted their 15th annual meeting for the business community focused on the region's economic outlook. Over 350 attendees were surveyed in real time regarding their expectations for the local economy in 2015, as well as plans for their respective businesses over the coming year.
SAN: 7.02 (-0.02)
Why Santander Is A Strong Buy From Here
Chris Lau - at Seeking Alpha - Tue Apr 07, 2:58AM CDT
SAN: 7.02 (-0.02)
Over 300 Local Business Leaders Discuss Massachusetts Economy at Santander and Greater Boston Chamber of Commerce Event
PR Newswire - Thu Apr 02, 2:03PM CDT
Santander Bank, N.A., and the Greater Boston Chamber of Commerce today hosted their 15th annual meeting for the business community focused on the region's economic outlook. Over 300 attendees were surveyed in real time regarding their expectations for the local economy in 2015 as well as plans for their respective businesses over the coming year.
SAN: 7.02 (-0.02)
Can Lender Santander Consumer USA Rev Up Car Loans?
at Investor's Business Daily - Tue Mar 31, 4:47PM CDT
When it comes to making auto loans to nonprime borrowers, Santander Consumer USA Holdings has been moving in the fast lane without hitting many speed bumps. Santander Consumer USA (SC), which went public in January 2014, is a consumer finance company...
SAN: 7.02 (-0.02), SC: 22.68 (+0.05), CACC: 211.50 (+5.39), FCAU: 16.29 (+0.02), IX: 82.78 (+3.06)
Why I Am Sticking With Santander
Nelson Alves - at Seeking Alpha - Tue Mar 31, 1:30AM CDT
SAN: 7.02 (-0.02)
Banco Santander Down 20.4% Since SmarTrend Downtrend Call (SAN)
Comtex SmarTrend(R) - Mon Mar 30, 9:35AM CDT
SmarTrend identified a Downtrend for Banco Santander (NYSE:SAN) on September 29th, 2014 at $9.47. In approximately 6 months, Banco Santander has returned 20.38% as of today's recent price of $7.54.
SAN: 7.02 (-0.02)
BoE unveils U.K. bank stress tests
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:17AM CDT
BCS: 15.35 (+0.06), SAN: 7.02 (-0.02), HSBC: 45.61 (+0.01), RBS: 10.53 (-0.06), LYG: 4.75 (-0.03)
Pre-Market Scans on Banks Stocks -- Banco Santander, Lloyds Banking, HSBC Holdings, Synovus Financial, and Citizens Financial
PR Newswire - Mon Mar 30, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SAN: 7.02 (-0.02), CFG: 25.49 (+0.45), SNV: 28.21 (+0.06), HSBC: 45.61 (+0.01), LYG: 4.75 (-0.03)
'Fast Money' Recap: The 3 Reasons Stocks Tanked Wednesday
at The Street - Thu Mar 26, 4:00AM CDT
The trading panel discussed the declines in biotech, transports and semiconductors.
FDX: 170.01 (+0.10), BIIB: 423.57 (+1.46), MU: 29.50 (+0.95), OIH: 36.92 (+0.42), XBI: 232.63 (-0.32), AMGN: 169.10 (+0.64), BNO: 22.89 (+0.29), IBB: 363.84 (-0.66), SMH: 57.23 (+1.02), INTC: 32.70 (+0.27), TLT: 127.72 (-1.98), CELG: 115.54 (+0.72), NVDA: 22.31 (+0.25), SAN: 7.02 (-0.02), SAVE: 77.25 (+0.19), GILD: 104.18 (-1.02), QCOM: 68.94 (+0.37), IYT: 158.66 (+0.89)
Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age
PR Newswire - Wed Mar 25, 11:15AM CDT
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved use of Quadracel(TM) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age.
SAN: 7.02 (-0.02), SNY: 51.59 (+0.03)
Santander: Global Retail Bank With Leading Cost Efficiency
Junius - at Seeking Alpha - Wed Mar 25, 6:52AM CDT
SAN: 7.02 (-0.02)
